Japan-based clinical-stage biopharmaceutical company that sources, develops, and commercializes innovative medicines for central nervous system conditions, addressing gaps in access to globally approved treatments
Japan-based clinical-stage biopharmaceutical company that sources, develops, and commercializes innovative medicines for central nervous system conditions, addressing gaps in access to globally approved treatments. Its portfolio includes pitolisant for narcolepsy and excessive daytime sleepiness, and Spydia (diazepam nasal spray) for status epilepticus. Acquired by Viatris in October 2025.